Picture [iito] No Tracking 650x80px
Document › Details

Vaccibody AS. (6/21/13). "Press Release: Vaccibody Raised 733.000 €".

Organisations Organisation Vaccibody AS
  Organisation 2 Cobra Biologics Ltd.
  Group Cobra Biologics (Group)
Products Product VB10.16 cancer vaccine
  Product 2 cancer vaccine
Index term Index term Vaccibody–SEVERAL: investment, 201306 private placement €733k to existing investors
Person Person Brekke, Ole Henrik (Vaccibody 201207 CEO)

In a private share issue placement in June Vaccibody raised 733.000 € from existing owners. The funding will be allocated to the company's development of VB10.16, a therapeutic vaccine against cervical cancer.

During the last 6 months Vaccibody has obtained significant progression with conclusive data in animal models on superior therapeutic effect of VB 10.16 and in April Vaccibody partnered with Cobra Biologicals for the GMP production of VB 10.16 (Read more:

"This funding will take us through the planned GLP safety and toxicity studies, allowing us to commence our first-in-man study with VB 10.16 in 2014. It is indeed exciting times for Vaccibody." CEO Ole Henrik Brekke, says in a comment.

Record changed: 2016-01-10


Picture [iito] Plain Stupid Simple 650x80px

More documents for Vaccibody AS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top